Predicting human pharmacokinetics of liposomal temoporfin using a hybrid in silico model

Nanomedicine Ex Machina: Between Model-Informed Development and Artificial Intelligence

“…Later the model was used to establish in vitro-in vivo correlations for liposomal nanocarrier formulations (61). Earlier model designs were applied to nanocrystal formulations and liposomes as well (62,63). A PBPK-based alternative is offered by GastroPlus TM (www.simulations-plus.com), PK-SIM R (www.systemsbiology.com), and Simcyp R (www.simcyp.com).…”

Testing the In-Vitro Product Performance of Nanomaterial-Based Drug Products: View of the USP Expert Panel

“…Due to the limited volume of the inner chamber, only a certain dose range can be injected into the donor compartment (depending on the drug load of the dispersed dosage form). So far, the setup has been evaluated for testing the drug release from nanoparticles (21,26,27), liposomes (3,9), nanocrystals (7), and polymer micelles, using buffers (21) and biorelevant dissolution media (3,7,9,26).…”

In-Vitro Product Performance of Parenteral Drug Products: View of the USP Expert Panel

“…One study developed a method to study amphotericin B release from liposomes by adding γ-cyclodextrin to a pH 7.4 HEPES buffer containing sucrose and NaN3 to prevent amphotericin B precipitation. This media in combination with an increase in media temperature raised to 55° enabled drug release within 24 h without affecting the liposome structure (37). Jablonka et al suggested the use of phosphate-buffered saline supplemented with cyclodextrins and fetal bovine serum (9,38).…”